Table 1.
Clinical characteristics of the study patients.
| Variable | Study population (n = 106) |
|---|---|
| Age (years) | 57 (range 22–80) |
| Male sex | 69 (65.1%) |
| Primary tumor location | |
| Right side | 21 (19.8%) |
| Left side | 85 (80.2%) |
| RAS wild-type | 106 (100%) |
| BRAF wild-type | 106 (100%) |
| Disease setting | |
| Recurrent | 10 (9.4%) |
| Initially metastatic | 96 (90.6%) |
| Treatment line | |
| 1st line | 89 (84.0%) |
| 3rd line | 17 (16.0%) |
| Best response | |
| Complete response | 7 (6.6%) |
| Partial response | 78 (73.6%) |
| Stable disease | 12 (11.3%) |
| Progressive disease | 9 (8.5%) |
| Treatment regimen | |
| Cetuximab + FOLFIRI* | 74 (69.8%) |
| Cetuximab + FOLFOX† | 5 (4.7%) |
| Cetuximab + Irinotecan | 12 (11.3%) |
| Cetuximab alone | 15 (14.2%) |
*5-fluorouracil plus irinotecan.
†5-fluorouracil plus oxaliplatin.